AUC

:   area under the curve

DAVID

:   database for annotation, visualization, and integrated discovery

DEM

:   differentially expressed miRNA

GC

:   gastric cancer

GEO

:   gene expression omnibus

GO

:   Gene Ontology

KEGG

:   Kyoto Encyclopedia of Genes and Genomes

miR‐17

:   hsa‐miR‐17

miRNA

:   microRNA

PPI

:   protein--protein interaction

ROC

:   receiver operating characteristic

RPM

:   reads per million

SMD

:   standard mean difference

SNR

:   signal‐to‐noise ratio

SROC

:   summary receiver operating characteristic

TCGA

:   The Cancer Genome Atlas

Gastric cancer (GC) ranks as the second most frequent cancer and is the second leading cause of cancer‐related death, following lung and bronchus cancer, in China [1](#feb412496-bib-0001){ref-type="ref"}. The definite clinical diagnosis depends on upper‐abdominal endoscopy with biopsy and cytological examination, with a diagnostic accuracy of approximately 95--99% for both types of GC [2](#feb412496-bib-0002){ref-type="ref"}. Nevertheless, limited methods exist for screening, early diagnosis, and recurrence monitoring with reduced discomfort and increased detection rate. Even the most prevalent blood biomarkers for gastrointestinal tumors, such as CEA, CA19‐9, and CA72‐4, often disappoint clinicians and GC patients because their positive detection rate is no more than 41% [3](#feb412496-bib-0003){ref-type="ref"}. It is well known that GC tumorigenesis, progression, and metastasis are highly related to dysregulated gene expression. Thus, identifying genes that are differentially expressed at the DNA and RNA levels between tumor and normal tissues may benefit the diagnosis, prognosis, and prediction of GC and help elucidate the molecular mechanisms underlying oncogenesis and therapeutic strategies [4](#feb412496-bib-0004){ref-type="ref"}, [5](#feb412496-bib-0005){ref-type="ref"}.

MicroRNAs (miRNAs) are small, noncoding RNAs that are 21--24 nucleotides in length and participate in post‐transcriptional regulation by binding to the 3′ untranslated regions of target genes, along with 5′ untranslated regions and coding sequences, leading to translational inhibition and cytoplasmic degradation [6](#feb412496-bib-0006){ref-type="ref"}, [7](#feb412496-bib-0007){ref-type="ref"}, [8](#feb412496-bib-0008){ref-type="ref"}. The aberrant expression of miRNAs is involved in multiple diseases, including various types of cancers. With advancements in research, miRNA‐mediated regulatory networks such as miRNAs--lncRNA--mRNA, miRNAs--circRNA--mRNA, and miRNA--mRNA--miRNA have been gradually used to elucidate the complicated molecular mechanisms underlying tumorigenesis, disease progression, invasion, and metastasis [9](#feb412496-bib-0009){ref-type="ref"}, [10](#feb412496-bib-0010){ref-type="ref"}, [11](#feb412496-bib-0011){ref-type="ref"}, [12](#feb412496-bib-0012){ref-type="ref"}, [13](#feb412496-bib-0013){ref-type="ref"}. In the past few years, studies in many fields have focused on the utilization of miRNAs in GC, ranging from diagnosis to therapies [14](#feb412496-bib-0014){ref-type="ref"}, [15](#feb412496-bib-0015){ref-type="ref"}. Accumulated knowledge has provided abundant resources for integrated studies to obtain more reliable information and more feasible measures in the field of medicine. In recent years, microarrays and sequencing technology have been extensively used as efficient tools for the identification of differentially expressed miRNAs (DEMs). Some widely available open access databases include The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO). Through searching the TCGA and GEO databases, we identified hsa‐miR‐17 (miR‐17) as a promising candidate for the diagnosis of GC and explored the associated molecular mechanism. Hence, this study aimed to comprehensively investigate the clinical significance and diagnostic value of miR‐17 in GC via meta‐analysis based on the two databases, the literature, and bioinformatics analysis.

Materials and methods {#feb412496-sec-0002}
=====================

miRNA‐seq data from TCGA database {#feb412496-sec-0003}
---------------------------------

Publicly available miRNA‐seq data on miRNA levels in GC samples were directly downloaded from TCGA data portal (<http://cancergenome.nih.gov/>) with file filters \[Transcriptome Profiling (Data Category), miRNA Expression Quantification (Data Type), miRNA‐Seq (Experimental Strategy)\], and case filters \[TCGA‐STAD (Project)\] on 12 December 2017. The corresponding clinical data were downloaded using Xena (<http://xena.ucsc.edu/>) from TCGA database. There were 491 files with a total of 436 stomach adenocarcinoma (STAD) samples. Furthermore, 41 cases had miRNA‐seq data from matched adjacent normal gastric mucosal tissues, whereas another 24 cases lacked pathological staging information. Finally, the miRNA‐seq data for 412 GC samples and 41 normal stomach mucosal samples were obtained for further analysis. Reads per million (RPM) values were extracted for 1882 mapped miRNAs in each sample. In addition, we cleaned the data using Python. DEMs between GC samples with pathological stages I--IV and normal stomach control samples were identified by calculating the fold change (FC) (\|log~2~(FC)\| \> 1 and *P* \< 0.05) with the [r]{.smallcaps} package [deseq]{.smallcaps}. One‐way analysis of variance or Student\'s *t*‐test was used to analyze the relationship between the relative miRNA expression levels and clinical characteristics with [spss statistics]{.smallcaps} version 20.0 (IBM Corp., Armonk, NY, USA). *P* \< 0.05 was considered statistically significant.

Microarray profiles from the GEO database {#feb412496-sec-0004}
-----------------------------------------

Microarray profiles (up to 11 January 2018) related to GC were obtained from the GEO database (<http://www.ncbi.nlm.nih.gov/geo/>) with the following search strategy: (miR OR miRNA OR microRNA) AND (malignant OR tumor OR tumour OR cancer OR carcinoma OR neoplasm OR neoplasms) AND (gastric OR stomach). The microarrays that met the following criteria were collected: (a) studies including at least 20 samples and (b) examination of miRNA expression in tissues, serum, or blood samples of GC patients. Microarrays that did not provide useful data for analysis were excluded. Finally, 12 GEO datasets, namely [GSE93415](GSE93415), [GSE78775](GSE78775), [GSE63121](GSE63121), [GSE54397](GSE54397), [GSE26595](GSE26595), [GSE33743](GSE33743), [GSE30070](GSE30070), [GSE28770](GSE28770), [GSE85589](GSE85589), [GSE59856](GSE59856), [GSE61741](GSE61741), and [GSE31568](GSE31568), were included in the present study. The DEMs between GC and healthy control samples in each GEO dataset were ranked according to the signal‐to‐noise ratio (SNR) using [morpheus]{.smallcaps} (<http://software.broadinstitute.org/morpheus/>), an online web tool. The top 250 DEMs in each direction were chosen for further analysis. An independent Student\'s *t*‐test or a paired *t*‐test was performed to calculate the difference in the levels of a particular miRNA between GC and healthy control samples. *P* \< 0.05 was considered statistically significant.

Real‐time PCR data of miR‐17‐5p from published studies {#feb412496-sec-0005}
------------------------------------------------------

A literature search (up to 11 January 2018) was conducted using the following databases: PubMed, Web of Science, EMBASE, and Cochrane. The following search strategy was used: (miR‐17 OR miRNA‐17 OR microRNA‐17 OR miR17 OR miRNA17 OR microRNA17 OR miR 17 OR mirna 17 OR microrna 17) AND (malignant OR cancer OR tumor OR tumour OR neoplasm OR carcinoma OR neoplasms) AND (gastric OR stomach). Eligible studies met the following criteria: (a) the studies were original articles; (b) the studies were on human GC patients; (c) miR‐17‐5p (or miR‐17) expression in GC tissues, serum, or plasma was measured by qRT‐PCR; (d) the required data could be determined or extracted from the original articles; (e) studies with the largest patient sample size were included if the data were published in multiple papers; and (f) the studies were published in English. Studies were excluded if they were published as an abstract, summary, case report, comment letter, review, or editorial. The assessment and selection of eligible studies were performed independently by two authors (G‐FH and Q‐WL). Controversial studies were reassessed by a third author (J‐XY) for consensus, and agreements were reached by discussion. After being carefully reviewed, the required data were extracted from the included studies using [getdata graph digitizer]{.smallcaps} version 2.26 (Germany).

Meta‐analysis {#feb412496-sec-0006}
-------------

The following data were extracted from each included study for meta‐analysis: sample number and the mean ± SD of the GC group and healthy control group, true positivity, false positivity, false negativity, and true negativity. [stata 12.0]{.smallcaps} (StataCorp, College Station, TX, USA) was used to conduct the meta‐analysis. The '[metan]{.smallcaps}' module of [stata 12.0]{.smallcaps} was used to determine the standardized mean differences (SMDs) and 95% confidence intervals (CIs) for pooled values. Heterogeneity was evaluated using Cochran\'s *Q* (chi‐square test) and the *I* ^2^ test. *P* \< 0.1 for the *Q* test and/or *I* ^2^ \> 50% were considered to indicate significant heterogeneity. If no obvious heterogeneity was detected, a fixed‐effects model was used. Otherwise, a random‐effects model was used. Additionally, subgroup analyses were performed based on the features of different studies to identify the source of heterogeneity. Publication bias was detected using Deeks\'s funnel plot asymmetry test. *P* ≥ 0.05 was considered to indicate the lack of publication bias. The summary receiver operating characteristic (SROC) curve was constructed according to the sensitivity and specificity.

Prediction of miRNA target genes {#feb412496-sec-0007}
--------------------------------

The prediction of possible miRNA target genes was performed using the following databases: miRTarbase [16](#feb412496-bib-0016){ref-type="ref"}, Tarbase v.8 [17](#feb412496-bib-0017){ref-type="ref"}, Targetscan7.1 [18](#feb412496-bib-0018){ref-type="ref"}, microT‐CDS [19](#feb412496-bib-0019){ref-type="ref"}, RNA22 2.0 [20](#feb412496-bib-0020){ref-type="ref"}, PicTar‐vet [21](#feb412496-bib-0021){ref-type="ref"}, miRDB [22](#feb412496-bib-0022){ref-type="ref"}, PolymiRTs [23](#feb412496-bib-0023){ref-type="ref"}, miRSystem [24](#feb412496-bib-0024){ref-type="ref"}, Targetminer (<http://www.isical.ac.in/~bioinfo_miu/targetminer20.htm>), miRecord (<http://c1.accurascience.com/miRecords/>), and miRWalk3.0 (<http://129.206.7.150/>). Genes overlapping in more than five databases were selected. It should be noted that target genes gained from Tarbase, mirTarBase, miRWalk3.0, and miRecord were experimentally validated. In addition, we identified differently expressed genes related to the pathological stage of GC using LinkedOmic [25](#feb412496-bib-0025){ref-type="ref"}, an online web tool based on TCGA, and collected the genes with *P* \< 0.05. Finally, the intersection of miRNA‐related genes and GC‐related ones was included for the bioinformatics analysis.

Integrative bioinformatics analysis {#feb412496-sec-0008}
-----------------------------------

The achieved target genes of miRNAs were pooled for Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis and Gene Ontology (GO) enrichment using Database for Annotation, Visualization and Integrated Discovery (DAVID) (<https://david.ncifcrf.gov/>). Protein--protein interaction (PPI) networks were constructed using [string]{.smallcaps} version 10.5 (<http://string-db.org/cgi/input.pl>).

Results {#feb412496-sec-0009}
=======

miR‐17 at the intersection of the TCGA and GEO datasets for GC {#feb412496-sec-0010}
--------------------------------------------------------------

Data for a total of 412 GC patients (266 males and 146 females) and 41 healthy control individuals were obtained from TCGA datasets, and RPM values of 1882 mapped miRNAs of each subject were extracted. The GC patients were divided into the following four groups, according to the pathologic stage: stage I (*n* = 58), stage II (*n* = 128), stage III (*n* = 183), and stage IV (*n* = 43). We compared the RPM data of 1882 miRNAs between the five groups. In the beginning, we attempted to identify miRNAs that were differentially expressed in all five groups. However, this strategy was not successful, as the intersection of DEMs was zero. Hence, we separately identified the DEMs between the healthy control and stage I--IV groups. The relevant volcano plots are shown in Fig. [1](#feb412496-fig-0001){ref-type="fig"}A. The four groups had 189 DEMs in common, including 165 upregulated miRNAs and 24 downregulated miRNAs identified from TCGA database. The corresponding Venn diagram and heat map of 189 DEMs are shown in Fig. [1](#feb412496-fig-0001){ref-type="fig"}B,C.

![Identification of DEMs in GC based on TCGA database. (A) Volcano plots between healthy controls and the stage I--IV groups in TCGA database. (qval = *P* value) (B) The corresponding Venn diagram of 189 DEMs. (C) The heat map of 189 DEMs, including 165 upregulated miRNAs and 24 downregulated miRNAs.](FEB4-8-1508-g001){#feb412496-fig-0001}

We searched the GEO database, and a total of 12 eligible GSE microarrays were included in the present study (Table [1](#feb412496-tbl-0001){ref-type="table"}). Because of the differences in sample types of GSE microarrays, the common DEMs were separately examined. Notably, we ignored the differences between the 3p and 5p arms of miRNAs when identifying the DEMs in GSE datasets on account of the names of miRNAs in the TCGA database. miR‐17 was the only miRNA appearing in all of the GSE datasets and the TCGA database. The corresponding Venn diagram is shown in Fig. [2](#feb412496-fig-0002){ref-type="fig"}. The 5p and 3p arms of miR‐17 among the top 500 miRNAs in GSE datasets according to the calculated SNR using [morpheus]{.smallcaps} are shown in Table [2](#feb412496-tbl-0002){ref-type="table"}; miR‐17‐5p and miR‐17‐3p are also known as miR‐17 and miR‐17\*, respectively [26](#feb412496-bib-0026){ref-type="ref"}, [27](#feb412496-bib-0027){ref-type="ref"}. We also searched the literature and found that miR‐17‐5p is more common and significant in GC than is miR‐17‐3p. Thus, we finally focused on miR‐17‐5p.

###### 

The relevant basic information and clinical data of 12 eligible GSE microarrays. The differences between the 3p and 5p arms of miRNAs were ignored when identified the DEMs in GSE datasets on account of the names of miRNAs in TCGA database

  Study                  Contributors, year          Country       Platform   Gastric cancer (*n*)   Healthy control (*n*)   MicroRNAs involved in study (*n*)   Sample type
  ---------------------- --------------------------- ------------- ---------- ---------------------- ----------------------- ----------------------------------- -------------
  [GSE93415](GSE93415)   Sierzega M *et al*., 2017   Poland        GPL19071   20                     20                      884                                 Tissue
  [GSE78775](GSE78775)   Yu B *et al*., 2016         China         GPL10850   28                     28                      851                                 Tissue
  [GSE63121](GSE63121)   Zhang X *et al*., 2014      China         GPL8786    15                     15                      847                                 Tissue
  [GSE54397](GSE54397)   Chang H *et al*., 2014      South Korea   GPL15159   16                     16                      1205                                Tissue
  [GSE26595](GSE26595)   Lee JS *et al*. 2013        South Korea   GPL8179    60                     8                       359                                 Tissue
  [GSE33743](GSE33743)   Carvalho J *et al*. 2012    Portugal      GPL14895   37                     4                       702                                 Tissue
  [GSE30070](GSE30070)   Kim CH *et al*. 2011        USA           GPL13742   90                     34                      414                                 Tissue
  [GSE28770](GSE28770)   Ahringer J *et al*. 2011    USA           GPL9269    22                     22                      470                                 Tissue
  [GSE85589](GSE85589)   Lee J *et al*., 2016        South Korea   GPL19117   7                      19                      825                                 Serum
  [GSE59856](GSE59856)   Kojima M *et al*., 2015     Japan         GPL18941   50                     150                     2555                                Serum
  [GSE61741](GSE61741)   Keller A, 2014              Germany       GPL9040    13                     94                      848                                 blood
  [GSE31568](GSE31568)   Keller A *et al*., 2011     Germany       GPL9040    13                     70                      863                                 blood

John Wiley & Sons, Ltd

![Identification of DEMs. miR‐17 was at the intersection of TCGA and GEO datasets for GC.](FEB4-8-1508-g002){#feb412496-fig-0002}

###### 

5p and 3p arms of hsa‐miR‐17 in the top 500 microRNAs according to SNR, as calculated in [morpheus]{.smallcaps}. Hsa‐miR‐17‐5p is also known as hsa‐miR‐17 and Hsa‐miR‐17‐3p is also known as hsa‐miR‐17\*

  Study                  Differentially expressed   
  ---------------------- -------------------------- -----
  [GSE93415](GSE93415)   Yes                        Yes
  [GSE78775](GSE78775)   Yes                        Yes
  [GSE63121](GSE63121)   Yes                        No
  [GSE54397](GSE54397)   Yes                        Yes
  [GSE26595](GSE26595)   Yes                        Yes
  [GSE33743](GSE33743)   Yes                        Yes
  [GSE30070](GSE30070)   Yes                        No
  [GSE28770](GSE28770)   Yes                        No
  [GSE85589](GSE85589)   Yes                        Yes
  [GSE59856](GSE59856)   Yes                        No
  [GSE61741](GSE61741)   Yes                        Yes
  [GSE31568](GSE31568)   No                         Yes

John Wiley & Sons, Ltd

The general flowchart is shown in Fig. [3](#feb412496-fig-0003){ref-type="fig"}. The present study is composed of four procedures performed sequentially, that is, the identification of GC‐related DEMs based on TCGA and GEO, the verification of clinical values base on comprehensive meta‐analysis, the prediction of target genes, and multiple bioinformatics analyses.

![General flowchart. The present study is composed of four procedures performed sequentially: the identification of GC‐related DEMs based on TCGA and GEO datasets, the verification of clinical values based on comprehensive meta‐analysis, the prediction of target genes, and multiple bioinformatics analyses.](FEB4-8-1508-g003){#feb412496-fig-0003}

miR‐17 expression in GC in TCGA database {#feb412496-sec-0011}
----------------------------------------

The expression level of miR‐17 was higher in the 412 GC tissues of different pathological stages than in the 41 normal gastric mucosal tissues (*P* \< 0.001) (Fig. [4](#feb412496-fig-0004){ref-type="fig"}A). The expression level results of miR‐17 for the 41 matched gastric cancer tissues are the same (Fig. [4](#feb412496-fig-0004){ref-type="fig"}B,C). The expression of miR‐17 in TCGA data was normalized using the logarithm. Furthermore, we explored the relationship between miR‐17 expression level and clinicopathological characteristics, with the results summarized in Table [3](#feb412496-tbl-0003){ref-type="table"}. No significant differences were observed among American Joint Committee on Cancer T, N, M stages, age, and gender. Among GC types, miR‐17 expression level was increased in the tubular and papillary types of intestinal adenocarcinoma and reduced in the diffuse type of adenocarcinoma (*P* = 0.014; Fig. [4](#feb412496-fig-0004){ref-type="fig"}D and Table [3](#feb412496-tbl-0003){ref-type="table"}). The *P*‐value of the diagnostic power in the receiver operating characteristic (ROC) curve was \<0.001 (area under the curve (AUC) = 0.857, 95% CI: 0.808--0.905, *P* \< 0.001; Fig. [4](#feb412496-fig-0004){ref-type="fig"}E). Additionally, there were no significant differences based on survival analyses (hazard ratio = 1.186, 95% CI: 0.866--1.624, *P* = 0.289) (Fig. [4](#feb412496-fig-0004){ref-type="fig"}F).

![MiR‐17 expression in GC in TCGA database. The expression of miR‐17 in TCGA data was normalized using the logarithm. (A) Comparison of miR‐17 levels in 412 GC tissues and 41 normal gastric mucosal tissues in TCGA data. (B,C) Comparison of miR‐17 levels in 41 pairs of GC tissues and adjacent non‐tumor tissues. (D) Comparison of miR‐17 levels in different histological types of GC tissues. (E) The ROC curve of miR‐17 expression based on TCGA data (AUC = 0.857, 95% CI: 0.808--0.905, *P* \< 0.001). (F) Kaplan--Meier survival curves of miR‐17. A‐DT, adenocarcinoma diffuse type; A‐NOS, adenocarcinoma not otherwise specified; A‐SRT, adenocarcinoma signet ring Type; AUC, area under the curve; IA‐MT, intestinal adenocarcinoma mucinous type; IA‐NOS, intestinal adenocarcinoma not otherwise specified; IA‐PT, intestinal adenocarcinoma papillary type; IA‐TT, intestinal adenocarcinoma tubular type; OS, overall survival.](FEB4-8-1508-g004){#feb412496-fig-0004}

###### 

Relationship between the expression of miR‐17 and clinicopathological features in GC from TCGA. One‐way analysis of variance and Student\'s paired or unpaired *t*‐test were used. A‐DT, adenocarcinoma diffuse type; AJCC, American Joint Committee on Cancer; A‐NOS, adenocarcinoma not otherwise specified; A‐SRT, adenocarcinoma signet ring Type; IA‐MT, intestinal adenocarcinoma mucinous type; IA‐NOS, intestinal adenocarcinoma not otherwise specified; IA‐PT, intestinal adenocarcinoma papillary type; IA‐TT, intestinal adenocarcinoma tubular type

  Clinicopathological feature   *n*      hsa‐miR‐17 expression (RPM)                                  
  ----------------------------- -------- ----------------------------- ---------- ---------- -------- ---------
  Tissue (unmatched)            Normal   41                            333.692    159.356    −5.211   \<0.001
  Tumor                         412      1224.398                      1092.287                       
  Tissue (matched)              Normal   41                            333.692    159.356    −6.591   \<0.001
  Tumor                         41       1001.995                      602.321                        
  Age (years)                   \<60     124                           1086.228   999.872    −1.715   0.087
  ≥60                           283      1288.305                      1132.681                       
  Gender                        Male     266                           1254.781   1148.808   0.762    0.447
  Female                        146      1169.042                      982.366                        
  Histological type             IA‐TT    75                            1489.868   889.374    2.695    0.014
  IA‐PT                         8        1559.301                      723.730                        
  IA‐NO                         78       1292.949                      1076.012                       
  IA‐MT                         22       913.999                       814.966                        
  A‐NOS                         147      1165.330                      1137.682                       
  A‐DT                          69       918.369                       770.191                        
  A‐SRT                         10       1626.048                      1917.403                       
  Pathological stage            I        58                            1357.578   1038.064   1.063    0.362
  II                            128      1122.297                      835.139                        
  III                           183      1285.011                      1259.853                       
  IV                            43       1090.728                      1065.495                       
  AJCC pathological T           T1       21                            1192.815   531.405    0.473    0.701
  T2                            87       1193.633                      1021.903                       
  T3                            188      1179.104                      865.113                        
  T4                            116      1326.595                      1483.968                       
  AJCC pathological N           N0       129                           1232.097   932.042    0.409    0.802
  N1                            109      1225.825                      1224.321                       
  N2                            82       1153.218                      806.988                        
  N3                            86       1243.926                      1343.528                       
  Nx                            6        1725.801                      1351.577                       
  AJCC pathological M           M0       364                           1221.083   1037.290   0.259    0.772
  M1                            29       1160.069                      1267.692                       
  Mx                            19       1386.078                      1734.700                       
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miR‐17‐5p expression in GC based on the GEO database {#feb412496-sec-0012}
----------------------------------------------------

A total of 12 GSE datasets, which consisted of 371 GC samples and 480 healthy control samples, were included in the present study (Table [1](#feb412496-tbl-0001){ref-type="table"}). Except for [GSE31568](GSE31568), the other 11 GEO datasets all contained miR‐17‐5p (Table [2](#feb412496-tbl-0002){ref-type="table"}). Interestingly, the expression level of miR‐17‐5p showed different trends in tissues and serum/blood. The expression of miR‐17‐5p was upregulated in five of the eight GEO datasets in which the sample type was tissue (Fig. [5](#feb412496-fig-0005){ref-type="fig"}A--H) but downregulated in all three GEO datasets in which the sample type was serum/blood (Fig. [5](#feb412496-fig-0005){ref-type="fig"}I--K).

![MiR‐17‐5p expression in GC based on the GEO database. (A--H) Expression levels of miR‐17‐5p in GC tissues from the GEO database. (I--K) Expression levels of miR‐17‐5p in GC serum or blood from the GEO database. N, normal gastric mucosal tissues or serum/blood from healthy volunteers; T, tumor tissues or serum/blood from GC patients.](FEB4-8-1508-g005){#feb412496-fig-0005}

Meta‐analysis of miR‐17‐5p expression in GC {#feb412496-sec-0013}
-------------------------------------------

The flowchart for the meta‐analysis is shown in Fig. [6](#feb412496-fig-0006){ref-type="fig"}. Regarding the difference in the expression of miR‐17‐5p between GC tissues and adjacent normal gastric mucosal tissues, in addition to the eight GEO datasets ([GSE93415](GSE93415), [GSE78775](GSE78775), [GSE63121](GSE63121), [GSE54397](GSE54397), [GSE26595](GSE26595), [GSE33743](GSE33743), [GSE30070](GSE30070), and [GSE28770](GSE28770)) in which the sample type analyzed was tissue and TCGA database, four additional published studies were included in the meta‐analysis [28](#feb412496-bib-0028){ref-type="ref"}, [29](#feb412496-bib-0029){ref-type="ref"}, [30](#feb412496-bib-0030){ref-type="ref"}, [31](#feb412496-bib-0031){ref-type="ref"}. The available data extracted from the original study that were utilized for the meta‐analysis are shown in Table [4](#feb412496-tbl-0004){ref-type="table"}. We determined the pooled SMD of miR‐17‐5p to be 0.695 (95% CI: 0.241--1.150, *P* = 0.003; Fig. [7](#feb412496-fig-0007){ref-type="fig"}A) using a random‐effects model. The *P*‐value of the heterogeneity test was \<0.001 (*I* ^2^ = 88.8%). No obvious publication bias was observed (Deeks\'s test: *P* = 0.257; Fig. [7](#feb412496-fig-0007){ref-type="fig"}B). The diagnostic accuracy was evaluated by plotting an SROC and calculating the AUC (AUC = 0.86, 95% CI: 0.82--0.88; Fig. [7](#feb412496-fig-0007){ref-type="fig"}C). The pooled sensitivity was 0.69 (95% CI: 0.54--0.80), and the pooled specificity was 0.90 (95% CI: 0.73--0.97). The forest plot of sensitivity and specificity is presented in Fig. [7](#feb412496-fig-0007){ref-type="fig"}D,E.

![Meta‐analysis flowchart.](FEB4-8-1508-g006){#feb412496-fig-0006}

###### 

Summary of the included studies in the meta‐analysis of miR‐17‐5p expression in GC patient tissues and serum/blood

  Study                  GC (*n*)   hsa‐miR‐17 expression   HC (*n*)   hsa‐miR‐17 expression   Sample type   Reference            
  ---------------------- ---------- ----------------------- ---------- ----------------------- ------------- ----------- -------- -------------------------------------------
  [GSE93415](GSE93415)   20         0.834                   1.089      20                      −0.656        0.998       Tissue   
  [GSE78775](GSE78775)   28         5.590                   0.441      28                      6.062         0.835       Tissue   
  [GSE63121](GSE63121)   15         6.606                   2.544      15                      7.507         0.819       Tissue   
  [GSE54397](GSE54397)   16         303.974                 308.340    16                      140.914       110.512     Tissue   
  [GSE26595](GSE26595)   60         12.437                  0.531      8                       12.531        0.190       Tissue   
  [GSE33743](GSE33743)   37         7.169                   0.306      4                       6.986         0.108       Tissue   
  [GSE30070](GSE30070)   90         −0.272                  0.278      34                      −0.4851       0.178       Tissue   
  [GSE28770](GSE28770)   22         399.372                 336.723    22                      285.519       229.129     Tissue   
  TCGA                   412        1224.398                1092.287   41                      333.692       159.356     Tissue   
  Chen *et al*.          40         1.794                   0.326      40                      0.916         0.239       Tissue   [31](#feb412496-bib-0031){ref-type="ref"}
  Zhang *et al*.         56         2.427                   1.664      56                      1.605         1.601       Tissue   [30](#feb412496-bib-0030){ref-type="ref"}
  Wu *et al*.            28         3.595                   2.699      28                      2.273         2.270       Tissue   [29](#feb412496-bib-0029){ref-type="ref"}
  Wang JL *et al*.       32         1.349                   0.489      32                      0.649         0.489       Tissue   [28](#feb412496-bib-0028){ref-type="ref"}
  [GSE85589](GSE85589)   7          2.640                   0.696      19                      3.014         0.477       Serum    
  [GSE59856](GSE59856)   50         3.722                   0.982      150                     4.393         0.730       Serum    
  [GSE61741](GSE61741)   13         6442.375                2017.992   94                      8987.255      4418.810    Blood    
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![Meta‐analysis of all of the available data of miR‐17‐5p expression level in GC tissues. (A) Forest plot of the meta‐analysis of miR‐17‐5p expression in GC tissues (SMD = 0.695, 95% CI: 0.241--1.150, *P* = 0.003). (B) Funnel plot of the meta‐analysis of miR‐17‐5p expression in GC tissues (Deeks\'s test: *P* = 0.257). (C) SROC curves for miR‐17‐5p in the diagnosis of GC (AUC = 0.86, 95% CI: 0.82--0.88). (D,E) Forest plot of sensitivity and specificity of miR‐17‐5p (pooled sensitivity = 0.69, 95% CI: 0.54--0.80; pooled specificity = 0.90, 95%CI: 0.73--0.97).](FEB4-8-1508-g007){#feb412496-fig-0007}

Next, we also conducted a meta‐analysis on the expression level of miR‐17‐5p in serum/blood in GC. Because there were no eligible studies and relevant TCGA data, only three GEO datasets ([GSE59856](GSE59856), [GSE61741](GSE61741), and [GSE85589](GSE85589)) in which the sample type was serum/blood were included in this meta‐analysis (Table [4](#feb412496-tbl-0004){ref-type="table"}). The pooled SMD of miR‐17‐5p was −0.774 (95% CI: −1.048 to −0.5, *P* \< 0.001; Fig. [8](#feb412496-fig-0008){ref-type="fig"}A) using a fixed‐effects model. The *P*‐value of the heterogeneity test was 0.777 (*I* ^2^ = 0%). Additionally, the publication bias was not statistically significant (Deeks\'s test: *P* = 0.43; Fig. [8](#feb412496-fig-0008){ref-type="fig"}B).

![Meta‐analysis of all of the available data for miR‐17‐5p expression levels in GC serum/blood. (A) Forest plot of the meta‐analysis of miR‐17‐5p expression in GC serum/blood (SMD = −0.744, 95% CI: −1.048 to −0.5, *P* \< 0.001). (B) Funnel plot of the meta‐analysis of miR‐17‐5p expression in GC serum/blood (Deeks\'s test: *P* = 0.43).](FEB4-8-1508-g008){#feb412496-fig-0008}

Identification of miR‐17‐5p target genes and bioinformatics analysis {#feb412496-sec-0014}
--------------------------------------------------------------------

Based on 12 target gene prediction databases and TCGA database, 288 prospective target genes of miR‐17‐5p were included (Fig. [3](#feb412496-fig-0003){ref-type="fig"}). According to the KEGG pathway analysis and GO enrichment in DAVID, a total of 33 KEGG pathways, 69 GO terms of biological processes, 28 GO terms of cellular components, and 25 GO terms of molecular function were identified (Fig. [9](#feb412496-fig-0009){ref-type="fig"}A--D). The top five KEGG pathway and GO terms are listed in Fig. [10](#feb412496-fig-0010){ref-type="fig"}. According to the results of our study, 288 genes were highly concentrated in the cAMP, phosphoinositide‐3‐kinase (PI3K)--Akt, Rap1, mitogen‐activated protein kinase (MAPK) signaling pathways and in pathways involved in cancer (*P* \< 0.05, Fig. [10](#feb412496-fig-0010){ref-type="fig"}A and Table [S1](#feb412496-sup-0001){ref-type="supplementary-material"}). In the GO enrichment, the genes were most likely involved in the biological processes of DNA‐templated transcription, the regulation of DNA‐templated transcription, the regulation of transcription from RNA polymerase II promoter and cell adhesion (*P* \< 0.05, Fig. [10](#feb412496-fig-0010){ref-type="fig"}B and Table [S2](#feb412496-sup-0002){ref-type="supplementary-material"}), in the cellular components of cytoplasm, plasma membrane, integral component of plasma membrane, actin cytoskeleton, and axon (*P* \< 0.05, Fig. [10](#feb412496-fig-0010){ref-type="fig"}C and Table [S3](#feb412496-sup-0003){ref-type="supplementary-material"}), in the molecular functions of protein binding, metal ion binding, transcription factor activity, sequence‐specific DNA binding, zinc binding, and calcium binding (*P* \< 0.05, Fig. [10](#feb412496-fig-0010){ref-type="fig"}D and Table [S4](#feb412496-sup-0004){ref-type="supplementary-material"}). The protein--protein interaction (PPI) networks of the 288 target genes are shown in Fig. [11](#feb412496-fig-0011){ref-type="fig"}. The top nine hub target genes of miR‐17‐5p with at least five connections in the PPI network were *PRKACB, ITGA4, PAFAH1B1, PIK3R1, ESR1, EFNB2, ATP2B1, AKT3, and LAMC1* (Fig. [12](#feb412496-fig-0012){ref-type="fig"}).

![Enriched KEGG pathways and Gene Ontology items of 288 overlapping target genes of miR‐17‐5p. (A) Enriched KEGG pathways. (B) Enriched biological processes. (C) Enriched cellular components. (D) Enriched molecular functions.](FEB4-8-1508-g009){#feb412496-fig-0009}

![Top five KEGG pathways and GO analysis items. (A) KEGG pathways. (B) Biological processes (BP). (C) Cellular components (CC). (D) Molecular functions (MF).](FEB4-8-1508-g010){#feb412496-fig-0010}

![Protein--protein interaction networks of the 288 overlapped target genes of miR‐17‐5p.](FEB4-8-1508-g011){#feb412496-fig-0011}

![Top nine hub target genes of miR‐17‐5p identified by the PPI network.](FEB4-8-1508-g012){#feb412496-fig-0012}

Discussion {#feb412496-sec-0015}
==========

GC, a fatal disease, has attracted increasing attention from clinicians worldwide because of its high morbidity and mortality rates. Despite advancements in life science and medicine, the achievements in diagnosis, treatment and understanding of the pathology do not yet satisfy the needs of patients for earlier diagnosis and longer survival time. In the present study, we integrated the information from next‐generation sequencing (TCGA) analysis and noncoding RNA profiling by microarray (GEO) in GC. As a promising miRNA candidate, miR‐17‐5p appeared in almost all of the datasets, suggesting that there may be some vital connection between miR‐17‐5p and GC.

miR‐17, as one of members of the miR‐17‐92 cluster, is located in an intron of nonprotein coding gene *miR17HG* (the miR‐17‐92 cluster host gene) on chromosome 13 in the human genome [32](#feb412496-bib-0032){ref-type="ref"}. The miR‐17‐92 cluster, also termed onco‐miR‐1, is upregulated in several types of cancer, such as lung, breast, stomach, prostate, colon, and pancreatic cancers [33](#feb412496-bib-0033){ref-type="ref"}. The other members of the miR‐17‐92 cluster (miR‐18a, miR‐19a, miR‐20a, miR‐19b‐1, and miR‐92a) were not present in all of the GEO and TCGA databases except miR‐17 in our study. As reported, upregulated miR‐17‐5p expression levels enhanced pancreatic cancer proliferation by altering cell cycle profiles [34](#feb412496-bib-0034){ref-type="ref"}. Low levels of miR‐17 and miR‐20a as a result of single nucleotide polymorphisms at the promoter of the miR‐17‐92 cluster may decrease the risk of colorectal cancer [35](#feb412496-bib-0035){ref-type="ref"}. In patients with recurrent breast cancer, miR‐17‐5p is upregulated in tumor tissues and significantly downregulated in serum as one of the exosomal miRNAs [36](#feb412496-bib-0036){ref-type="ref"}. In contrast, statistically significant reductions in the levels of miR‐17 and miR‐19a in plasma have been observed between early and advanced stages of breast cancer [37](#feb412496-bib-0037){ref-type="ref"}.

With regard to the expression of miR‐17‐5p in GC, the majority of studies considered that this miRNA is upregulated in GC tissues [28](#feb412496-bib-0028){ref-type="ref"}, [29](#feb412496-bib-0029){ref-type="ref"}, [30](#feb412496-bib-0030){ref-type="ref"}, [31](#feb412496-bib-0031){ref-type="ref"}, [38](#feb412496-bib-0038){ref-type="ref"}, [39](#feb412496-bib-0039){ref-type="ref"}, [40](#feb412496-bib-0040){ref-type="ref"}. Consistent with those previous studies, the meta‐analysis in our study revealed that miR‐17‐5p was significantly upregulated in GC tumors. A meta‐analysis of the miR‐17‐92 cluster in various cancers, including GC, indicated a poor prognosis in patients with high expression of this cluster [41](#feb412496-bib-0041){ref-type="ref"}. Another meta‐analysis identified 23 significantly upregulated miRNAs, including miR‐17, that were correlated with poor prognosis in gastrointestinal cancers [42](#feb412496-bib-0042){ref-type="ref"}. However, neither of the meta‐analyses evaluated the expression of miR‐17‐5p separately in GC. In addition, the expression level of miR‐17‐5p in serum/blood in GC remained controversial. The microarray data in the [GSE85589](GSE85589), [GSE59856](GSE59856), and [GSE61741](GSE61741) datasets suggested lower miR‐17‐5p levels in the serum/blood of GC patients than in healthy control individuals. In a study by Zeng *et al*., the serum levels of miR‐17 were significantly reduced in both GC (*n* = 40) and benign gastric disease (gastric ulcer and gastric polyp) (*n* = 32) patients compared with healthy control individuals (*n* = 36) [43](#feb412496-bib-0043){ref-type="ref"}. However, Zhou *et al*., by analyzing mononuclear cells collected from peripheral blood containing circulating tumor cells, concluded that miR‐17 and miR‐106a levels were significantly higher in preoperative (*n* = 41) and postoperative (*n* = 49) GC patients than in healthy volunteers (*n* = 27) [44](#feb412496-bib-0044){ref-type="ref"}. Wang *et al*. identified four miRNAs, including miR‐17‐5p, in serum‐circulating exosomes from a cohort of 20 healthy control individuals and 20 GC patients; however, according to this study, the upregulated expression of miR‐17‐5p had no statistical significance [45](#feb412496-bib-0045){ref-type="ref"}. Furthermore, Tsujiura *et al*. demonstrated that the plasma concentration of miR‐17‐5p without contamination by cellular nucleic acids was significantly higher in GC patients (*n* = 69) than in healthy controls (*n* = 30) [46](#feb412496-bib-0046){ref-type="ref"}. According to the results of our two independent meta‐analyses, miR‐17‐5p expression levels were upregulated in GC tissues but downregulated in the serum/blood of GC patients. Our hypothesis is that GC tumorigenesis may have an effect on the extracellular transport of miR‐10‐5p. However, further research is needed to explore possible mechanisms. Notably, serum/blood samples from 70 GC patients and 263 healthy controls, which came from only three independent studies, were included in the meta‐analysis of miR‐17‐7p expression. Thus, although we conducted a meta‐analysis of miR‐17‐5p expression levels in serum/blood in our study, further investigations are required to confirm the relevant results. However, in GC tissues, the increased expression level of miR‐17‐5p, which was verified in our study, still reveals a promising prospect for miR‐17‐5p as a biomarker in GC. The diagnostic accuracy was evaluated and miR‐17 had increased specificity and sensitivity (Fig. [7](#feb412496-fig-0007){ref-type="fig"}C--E).

To investigate the underlying molecular mechanism, we performed a comprehensive bioinformatics analysis. According to 12 miRNA target gene prediction databases and the relevant TCGA data, 288 genes were considered for further analysis. Based on KEGG pathway analysis and GO enrichment, several core pathways and GO terms displayed the potential to play a crucial role in GC. Nine hub target genes, namely *PRKACB, ITGA4, PAFAH1B1, PIK3R1, ESR1, EFNB2, ATP2B1, AKT3,* and *LAMC1,* may have a close association with the tumorigenesis, disease progression, invasion, and metastasis of GC.

Our study may be the first example of the integration of data from the GEO database, TCGA database, and published literature to investigate the possible differential expression of miRNAs and their potential molecular mechanisms in GC. The study identified some core pathways and genes in GC, which may facilitate the further exploration of mechanisms. However, there are some limitations to our study. First, the numbers of miRNAs detected in different GSE chips were different (Table [1](#feb412496-tbl-0001){ref-type="table"}), suggesting that some newly discovered miRNAs might be missing. And some miRNAs might be excluded because of our rigorous screening criteria. Second, the meta‐analysis of the expression of miR‐17‐5p in serum/blood of GC needed to be optimized because of insufficiently reliable studies at present. Third, the prediction of target genes was based on different algorithms. More experiments will be needed for validation or even correction and to confirm the KEGG pathway analysis and GO enrichment results.

In conclusion, we believe that miR‐17 may serve as a promising diagnostic marker for GC. miR‐17‐5p promotes the occurrence and development of GC by targeting certain downstream genes. Future studies should be focused on the functions and underlying pathways of miR‐17 in different GC sample types, such as tissue, serum, blood, circulating tumor cells, serum exosomes, and others, to further explore its utility in the diagnosis and molecular therapy of GC.
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